
Medtronic PLC



Performance data quoted presents past performance; past performance does not guarantee future results; the investment return and principal value of an investment will fluctuate; an investor's shares, when redeemed, may be worth more or less than their original cost; current performance may be lower or higher than quoted performance data.

Inc. Statement	2015	2016	2017	2018	2019	2020					TTM
Revenue	20.26B	28.83B	29.71B	29.95B	30.56B	28.91B	30.12B	31.69	3 31.23B	32.36B	33.00E
Operating Margin	22.49%	20.67%	20.15%	20.14%	21.70%	18.06%	16.25%	18.65%	6 18.67%	17.06%	17.41%
EBIT Margin	20.49%	19.85%	19.17%	22.77%	21.73%	17.80%	16.00%	19.16%	6 19.21%	17.17%	17.94%
Effective Tax Rate	23.26%	18.40%	12.56%	45.46%	10.53%	-18.52%	6.80%	8.27%	% 29.46%	23.42%	16.16%
Net Income	2.675B	3.538B	4.028B	3.104B	4.631B	4.789B	3.606B	5.039E	3.758B	3.676B	4.288E
EPS Basic	2.44	2.51	2.92	2.29	3.44	3.57	2.68	3.75	5 2.83	2.77	3.28
EPS Diluted	2.41	2.48	2.89	2.27	3.41	3.54	2.66	3.73	3 2.82	2.76	3.27
Balance Sheet	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024 L	ast Qtr
Total Assets	106.68B	99.64B	99.86B	91.39B	89.69B	90.69B	93.08B	90.98B	90.95B 8	39.98B	90.04E
Total Liabilities	53.46B	47.58B	49.53B	40.57B	39.48B	39.82B	41.48B	38.26B	39.28B 3	39.56B	41.33E
Financial Debt	35.96B	30.88B	33.37B	25.74B	25.30B	24.75B	26.32B	24.05B	24.30B 2	24.96B	28.28
Shareholders Equity	53.23B	52.06B	50.21B	50.72B	50.09B	50.74B	51.43B	52.55B	51.48B 5	50.21B	48.49E
Cash Flow	2015	2016	2017	2018	2019	2020) 202 1	202	2 2023	2024	TTN
Cash from Operations	4.902B	5.218B	6.88B	4.684B	7.007E	3 7.2348	6.24	3 7.346	B 6.039B	6.787B	7.195
Cash from Investing	-17.06B	2.245B	-1.571B	5.858B	-774.00N	1 -3.2038	3 -2.866	3 -1.659	B -3.493B	-2.366B	-2.007
Cash from Financing	15.95B	-9.543B	-3.283B	-11.95B	-5.431	8 -4.198	3 -4.136	8 -5.336	B -4.96B	-4.45B	-5.124
Free Cash Flow	4.331B	4.172B	5.626B	3.616B	5.873	6.021	8 4.8858	5.978	B 4.58B	5.20B	5.499E
Dividend	2015	2016	2017	2018	2019	2020	202	1 202	22 202	3 2024	I TTN
Dividend Per Share	1.22	1.52	1.72	1.84	2.00	2.1	6 2.3	2 2.	52 2.7	2 2.70	5 2.78
Payout Ratio	49.98%	60.46%	58.99%	80.35%	58.15%	60.439	6 86.52	% 67.14	4% 96.22	% 99.73%	6 -
Profitability	2015	2016	2017	2018	2019	2020	2021	2022	2 2023	2024	TTN
Return on Assets	3.70%	3.43%	4.04%	3.25%	5.11%	5.31%	3.92%	5.489	% 4.13%	4.06%	
Return on Equity	7.36%	6.72%	7.87%	6.14%	9.17%	9.48%	7.04%	9.669	% 7.20%	5 7.20%	
Return on Invested Capital	4.45%	4.11%	4.83%	3.87%	6.09%	6.34%	4.70%	6.519	% 4.92%	4.86%	
Estimates	Q3 20	025 (24 2025	Q1 2	026	Q2 2026	Q3 :	2026	2025	2026	2027
EPS	1.	605	1.323	1	.407	1.444	ļ	1.445	5.454	5.824	6.28
Revenue	8.8	52B	8.339B	8.7	750B	8.733E	8 8	.740B	33.57B	35.10B	36.85
Shareholder Friendl	iness		Liqui	dity				Shor	rt Interes	t	
Dividend Yield	3.019	6	Quick	Ratio An	nual	1.31	D	Short	t Interest		14.00N

2.033

11.15B

7.727

onarcholaci i ficha	inicoo	Elquidity
Dividend Yield	3.01%	Quick Ratio Annual
Net Payout Yield	6.51%	Current Ratio Ann
Net Buyback Yield	3.51%	Working Capital Ann
Debt Paydwn Yield	-0.59%	EBIT/Int Expense Ann

Short Interest	
Short Interest	14.00M
Days to Cover Short	1.839
Percent of Float Short	1.09%
% of Shr Outst Short	1.09%



One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales. *Currency: USD*

ounency: 000									
Symbol: MDT Sector: Health Care Industry: Health Care Equipment & Supplies Consensus Rating: Outperform Y-Rating: Neutral Last Fiscal Period:				Price - Feb. 14, 2025 92.81 Price Target 94.96 52 Week High - Jan. 28, 2025 93.08 52 Week Low - July 9, 2024 75.96 Market Cap 119.01B					
Performance	1M	3M		1Y*	3Ү*	5Y*	10Y*		
Total Return	8.87%	8.85%		14.69%	0.00%	-1.84%	4.67%		
Price Return	8.87%	7.92%	16.19%	10.91%	-3.20%	-4.58%	2.12%		
					*Figure	es are ann	ualized.		
		Tota	al Returns		Valuation (TTM)				
Comparables	1	γ*	ЗҮ*	5Y*	P	/E	P/S		
MDT	14.6	9%	0.00%	-1.84%	28.3	38	3.684		
BSX			35.42%	20.19%	84.8	89	9.415		
NVRO			-56.68%	-47.24%			0.5007		
ABT			4.07%	9.73%	17.0	17	5.444		
						ualized.			
Growth				3Ү			10Y		
Revenue				3¥ 2.43%	5) 1.16%		6.65%		
				4.09%	-3.60%		1.37%		
Operating Income EPS Basic				4.09%	-3.00%		-0.99%		
Total Dividends Paid					-4.24%				
				5.52%			12.63%		
Book Value				-0.79%	0.05%		9.95%		
Total Assets				-1.12%	0.06%	Ď	9.02%		
Valuation	т	тм	3Y Me	d. !	5Y Med.	In	d. Avg.		
PE Ratio	28	3.38	27.4	43	28.86		-		
PS Ratio	3.	684	3.5	48	3.834				
PB Ratio	2.	454	2.1	87	2.375		-		
Price/FCF	22	2.10	22.	85	24.32				
EV/EBITDA	16	5.30	14.	86	15.75				
EV/EBIT	23	8.57	21.	50	22.80		-		
EV/Revenue	4.	228	4.0	56	4.307				
EV/FCF	25	5.37	25.	98	27.20				
EV/Assets	1.	499	1.4	20	1.420		-		
P/E Forward	17	7.02					-		
P/S Forward	3.	546					-		
PEG Forward	0.1	744					-		
Risk				3Y		Ϋ́	10Y		
Beta				0.7912	0.84		0.7642		
Standard Deviation				21.96%	21.77		20.74%		
Historical Sharpe Ra	tio			-0.2366	-0.204		0.156		
Max Drawdown				45.10%	45.10		45.10%		
VaR 5%				2.24%	2.28		2.16%		
Historical Sortino				-0.4779	-0.40	05	0.2228		

2025 YCharts, Inc. All Rights Reserved. YCharts, Inc. (YCharts') is not registered with the U.S. Securities and Exchange Commission (or with the securities regulatory authority or body of any state or any other jurisdiction) as an investment adviser, broker-dealer or in any other capacity, and does not purport to provide investment advice or make investment recommendations. This report has been generated using data manually input by the creator of this report combined with data and calculations from YCharts.com and is intended solely to assist you or your investment or other adviser(s) in conducting investment research. You should not construe this report as an offer to buy or sell, as a solicitation of an offer to buy or sell, or as a recommendation to buy, sell, hold or trade, any security or other financial instrument. For further information regarding your use of this report, please go to: https://get.ycharts.com/disclosure/